ITM announces positive Phase 3 results for ITM-11 in neuroendocrine tumours, paving the way for a potential new treatment ...
Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...
Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...
Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced ...
Comparative outcomes of neuroendocrine tumors in the historically underserved population of Bronx, NY: Montefiore Einstein Comprehensive Cancer Center. Pamrevlumab ...
Rare cancers are less known and pose challenges due to limited research and diagnostic difficulties. Environmental factors, ...
Clinicopathological factors related to survival in gastroenteropancreatic neuroendocrine tumors (GEP-NET): 20 years experience in the American British Cowdray Medical Center. This is an ASCO Meeting ...
After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...
Discover ITM and its cancer candidate ITM-11 as it brings one of the first big wins the radiopharmaceutical sector awaits.
Afinitor plus Somatuline showed an improved survival compared with Afinitor monotherapy in patients with gastroenteropancreatic neuroendocrine tumors.
In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback